News
Chief Medical Officer at Central DuPage Hospital Dr. Tom Moran joins Bob Sirott to talk about the risks of sitting for too ...
This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...
Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine.
A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty ...
Semaglutide, a drug commonly taken for weight loss, showed marked benefits for most patients in a trial for metabolic ...
The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...
A decision is expected in the fourth quarter of 2025.
Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...
Semaglutide - the active ingredient in medications like Ozempic and WeGovy - is only FDA approved for Type-2 diabetes, but ...
CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results